课题基金 / 基金详情

Portable Ultrasonometer for Osteoporosis Assessment

Portable Ultrasonometer for Osteoporosis Assessment
用于骨质疏松症评估的便携式超声波仪
批准号:
7913453
负责人:
Armen Sarvazyan
金额:
$21.95万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-09-30 至 2011-08-31

项目摘要

项目成果

Armen Sarvazyan的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):骨质疏松症是一种严重的公共卫生问题,是由衰老和某些药物的副作用引起的。缺乏足够的手段早期发现骨退化是最大限度地减少药物治疗对骨骼系统的副作用以及监测骨质疏松症治疗的最关键问题。骨超声扫描仪(BUSS)是基于测量长骨中各种模式的轴向声波的传播特性,用于骨质疏松症的早期检测和监测。临床试验证实了BUSS能够区分骨萎缩的不同阶段,特别是从正常到骨质减少的变化。目前其他超声技术无法区分这种早期骨质退化,但在监测药物诱导或代谢性加速骨质流失方面尤为重要。这些创新在BUSS中实施,并在已发布和未决的美国专利以及Artann的许多出版物中进行了描述,包括:同时使用在宽频带中产生的各种声波模式,骨检查的轴向扫描模式;综合分析了不同比例海绵状和致密状构件沿骨传播的体波、面波和导波波形。Artann已经建立了一系列战略关系,将提供工程、临床、监管、报销、制造和营销支持/专业知识,以实现项目目标。我们的合作伙伴包括:梅奥诊所,罗切斯特,明尼苏达州和健康智能医疗中心,费城,宾夕法尼亚州,进行FDA申请所需的验证和规范临床研究;Hogan and Hartson, LLP,监管和报销合作伙伴,为完成多项临床研究和FDA申请提供指导;可扩展解决方案集团,一家专注于满足FDA和国际标准所需的设计控制的法规遵从公司;进行验证和验证测试和危害分析;和Healthcare Investors, LLC承诺为BUSS技术的商业化提供必要的财务和管理资源,以补充NIH对该项目的支持。实现该项目的目标将确保便携式,易于使用和具有成本效益的BUSS的市场引入,用于早期骨质疏松症的检测,药物引起的骨质恶化的管理和药物治疗的监测。公共卫生相关性:开发一种监测由衰老引起的骨退化以及各种药物副作用的方法,将通过诊断高危患者和干预预防进一步的骨质流失、骨脆弱性增加和使人衰弱的骨折,为社会带来实质性的好处。骨质疏松症已知影响了4400万美国人,导致150万例骨折,估计每年造成180亿美元的损失。由于缺乏能够在骨矿物质含量发生重大变化之前评估骨退化早期阶段的诊断工具,有效利用药物武器治疗骨质疏松症的能力受到严重损害。实验室测试和临床研究表明,Artann实验室开发的骨超声扫描仪(BUSS)对早期骨质流失和骨结构变化高度敏感。BUSS可以理想地用于监测骨质退化和早期识别那些有骨质疏松风险的人。该项目的长期目标是将BUSS技术推向市场,同时满足重要的临床和患者需求。
英文摘要
DESCRIPTION (provided by applicant): Osteoporosis induced by aging as well as a side effect of certain drugs is a serious public health problem. The lack of adequate means for early detection of bone deterioration is the most critical issue in the problem of minimization of side effects of pharmaceutical treatment on skeletal system as well as in monitoring osteoporosis therapy in general. Bone UltraSonic Scanner (BUSS) is intended for the early detection and monitoring of osteoporosis based on the measurements of propagation characteristics of various modes of axial acoustic waves in long bones. Clinical testing confirmed BUSS's capability to discriminate between stages of bone atrophy, particularly the changes from normal to osteopenia. This early stage of bone deterioration is not distinguished by other current ultrasonic techniques but is particularly important in monitoring drug induced or metabolic accelerated bone loss. The innovations, which are implemented in BUSS and described in the issued and pending U.S. patents and in numerous publications of Artann, include: simultaneous use of various modes of acoustic waves generated in a wide frequency band, axial scanning mode of bone examination; and comprehensive analysis of waveforms of bulk, surface and guided ultrasonic waves propagating along the bone with varied proportion of spongy and compact components. Artann has established a number of strategic relationships that will provide engineering, clinical, regulatory, reimbursement, manufacturing and marketing support/expertise to accomplish the goals of the project. Our partners includes: Mayo Clinic, Rochester, MN, and Health Smart Medical Center, Philadelphia, PA, to conduct validation and normative clinical studies necessary for FDA application; Hogan and Hartson, LLP, the regulatory and reimbursement partners to provide direction in completing multiple clinical studies and FDA submissions; Scalable Solutions Group, a regulatory compliance company with the focus on design control needed to satisfy FDA and international standards; Intertek tol conduct verification & validation testing and hazard analysis; and Healthcare Investors, LLC that made a commitment to provide necessary financial and managerial resources to the commercialization of the BUSS technology complementing NIH support of the project. Accomplishing the objectives of the project will secure market introduction of the portable, easy to use and cost effective BUSS for the early stage osteoporosis detection, management of drug-induced bone deterioration, and monitoring of pharmaceutical treatment. PUBLIC HEALTH RELEVANCE: Development of a method for monitoring of bone deterioration induced by aging as well as a side effect of various drugs will provide a substantial benefit to society by diagnosing at risk patients and intervening to prevent further bone loss, increased bone fragility and debilitating fracture. Osteoporosis is known to affect 44 million Americans resulting in 1.5 million fractures and an estimated $18 billion in costs each year. Effective use of the pharmaceutical armament to treat osteoporosis is substantially impaired by the lack of the diagnostic tools that could assess early stages of bone deterioration preceding gross changes in bone mineral content. Laboratory tests and clinical studies have shown that Bone Ultrasonic Scanner (BUSS) developed at Artann Laboratories is highly sensitive to early stages of bone loss and changes in bone structure. BUSS could be ideally suited for the monitoring bone deterioration and early identification of those at a risk for osteoporosis. The long-term goal of this project is to move the BUSS technology to market while also meeting a significant clinical and patient need.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Muscle viscosity as a protective mechanism for absorbing mechanical shock
  • 批准号:
    8569231
  • 项目类别:
  • 资助金额:
    $16.26万
  • 财政年份:
    2013
  • 负责人:
    Armen Sarvazyan
  • 依托单位:
Muscle viscosity as a protective mechanism for absorbing mechanical shock
  • 批准号:
    8734322
  • 项目类别:
  • 资助金额:
    $19.28万
  • 财政年份:
    2013
  • 负责人:
    Armen Sarvazyan
  • 依托单位:
Portable device for monitoring water balance in elderly
  • 批准号:
    8591530
  • 项目类别:
  • 资助金额:
    $52.64万
  • 财政年份:
    2013
  • 负责人:
    Armen Sarvazyan
  • 依托单位:
Portable device for monitoring water balance in elderly
  • 批准号:
    8704442
  • 项目类别:
  • 资助金额:
    $46.76万
  • 财政年份:
    2013
  • 负责人:
    Armen Sarvazyan
  • 依托单位:
海外基金